These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16690737)

  • 1. Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay.
    Moriyama M; Hayashi N; Ohyabu C; Mukai M; Kawano S; Kumagai S
    Clin Chem; 2006 Jul; 52(7):1423-6. PubMed ID: 16690737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays.
    Owen WE; Roberts WL
    Clin Chem; 2004 Jan; 50(1):257-9. PubMed ID: 14709671
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical application of the different cross-reactivities of anti-insulin antibodies to insulin lispro to evaluate endogenous insulin secretion.
    Yoshida R; Ohkubo K; Akehi Y; Harada S; Shinohara K; Kawashima H; Ono J; Matsunaga A
    Clin Chim Acta; 2013 Jan; 415():250-4. PubMed ID: 23159841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity of insulin analogues with three insulin assays.
    Dayaldasani A; Rodríguez Espinosa M; Ocón Sánchez P; Pérez Valero V
    Ann Clin Biochem; 2015 May; 52(Pt 3):312-8. PubMed ID: 25172526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro.
    Sapin R; Le Galudec V; Gasser F; Pinget M; Grucker D
    Clin Chem; 2001 Mar; 47(3):602-5. PubMed ID: 11238323
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic performance of the ARCHITECT C-Peptide immunoassay.
    Schultess J; van Duren C; Martens M; Costa M; Llop T; Martí T; Eppinger M; Hausmann M; Krack W; Dhein J
    Clin Chem Lab Med; 2009; 47(7):834-41. PubMed ID: 19496736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification.
    Heurtault B; Reix N; Meyer N; Gasser F; Wendling MJ; Ratomponirina C; Jeandidier N; Sapin R; Agin A
    Clin Chem Lab Med; 2014 Mar; 52(3):355-62. PubMed ID: 24150210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical diagnostic performance of light-initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody.
    Yang S; Yang R; Zhang S; Liu D; Zhou J; Wang T; Cui L
    J Clin Lab Anal; 2019 Sep; 33(7):e22928. PubMed ID: 31148296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ARCHITECT Chagas(®): a new diagnostic tool in Chagas disease].
    Iborra-Bendicho MA; Albert-Hernández M; Márquez-Contreras C; Segovia-Hernández M
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):463-5. PubMed ID: 22446008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay.
    Wallemacq P; Maine GT; Berg K; Rosiere T; Marquet P; Aimo G; Mengozzi G; Young J; Wonigeit K; Kretschmer R; Wermuth B; Schmid RW
    Ther Drug Monit; 2010 Apr; 32(2):145-51. PubMed ID: 20216110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.
    Gray MA; Cooke RR; Weinstein P; Nacey JN
    Ann Clin Biochem; 2004 May; 41(Pt 3):207-12. PubMed ID: 15117434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a noncompetitive electrochemiluminescence-based immunoassay (ECLIA) for specific determination of insulin lispro (Humalog®) in human serum to support pharmacokinetic assessments.
    Simmons E; Johnson D; Delhaye R; Colwell J; Clor E; Santa P; Bowsher RR
    J Immunoassay Immunochem; 2019; 40(3):314-327. PubMed ID: 30924380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
    Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
    Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone metabolite causes falsely increased progesterone in the Abbott Architect immunoassay.
    Sarpong KAN; Hee Kim S; McCartney CR; Wiencek JR; Bazydlo LAL
    Clin Biochem; 2024 Apr; 126():110747. PubMed ID: 38484829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Procalcitonin Assay on the Abbott Architect i1000.
    Pagaduan JV; Tam E; Devaraj S
    J Appl Lab Med; 2019 May; 3(6):936-942. PubMed ID: 31639685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay.
    Krintus M; Kozinski M; Boudry P; Capell NE; Köller U; Lackner K; Lefèvre G; Lennartz L; Lotz J; Herranz AM; Nybo M; Plebani M; Sandberg MB; Schratzberger W; Shih J; Skadberg Ø; Chargui AT; Zaninotto M; Sypniewska G
    Clin Chem Lab Med; 2014 Nov; 52(11):1657-65. PubMed ID: 24897400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method.
    Johnson-Davis KL; De S; Jimenez E; McMillin GA; De BK
    Ther Drug Monit; 2011 Aug; 33(4):453-9. PubMed ID: 21743377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay.
    Wallemacq P; Goffinet JS; O'Morchoe S; Rosiere T; Maine GT; Labalette M; Aimo G; Dickson D; Schmidt E; Schwinzer R; Schmid RW
    Ther Drug Monit; 2009 Apr; 31(2):198-204. PubMed ID: 19258928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods.
    Monge M; Jean G; Bacri JL; Lemaitre V; Masy E; Joly D; Souberbielle JC
    Clin Chem Lab Med; 2009; 47(3):362-6. PubMed ID: 19199835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-site, multi-country evaluation of analytical and operational performance of a low-mid volume chemiluminescent immunoassay analyzer.
    De Keijzer MH; Perkins S; Motta V; Morelli D; Cristol JP; Dupuy AM; Hong Y; Watanabe S; Waerdt C; Grunewald RW
    Clin Lab; 2009; 55(9-10):363-70. PubMed ID: 20099573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.